<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "1: risk factors", fill: "#00308f"},
{source: "1: risk factors", target: "1: Genelabs ", fill: "#00308f"},
{source: "1: Genelabs ", target: "1: shareholders", fill: "#00308f"},
{source: "1: risk factors", target: "2: comprehensively address", fill: "#fff700"},
{source: "2: comprehensively address", target: "2: following risks", fill: "#fff700"},
{source: "2: following risks", target: "2: particular should", fill: "#fff700"},
{source: "2: particular should", target: "2: Annual Report ", fill: "#fff700"},
{source: "2: Annual Report ", target: "2: raise additional capital within", fill: "#fff700"},
{source: "2: raise additional capital within", target: "2: next several months", fill: "#fff700"},
{source: "2: next several months", target: "2: timely secure adequate funds on", fill: "#fff700"},
{source: "2: timely secure adequate funds on", target: "2: operations", fill: "#fff700"},
{source: "2: operations", target: "2: continue as", fill: "#fff700"},
{source: "2: comprehensively address", target: "5: additional", fill: "#00308f"},
{source: "5: additional", target: "5: entering into", fill: "#00308f"},
{source: "5: entering into", target: "5: new collaboration", fill: "#00308f"},
{source: "5: new collaboration", target: "5: hepatitis", fill: "#00308f"},
{source: "5: hepatitis", target: "5: existing corporate collaboration andor", fill: "#00308f"},
{source: "5: existing corporate collaboration andor", target: "5: arrangements", fill: "#00308f"},
{source: "5: arrangements", target: "5: seek additional funds will", fill: "#00308f"},
{source: "5: additional", target: "22: comply with", fill: "#808000"},
{source: "22: comply with", target: "22: shareholders equity requirement", fill: "#808000"},
{source: "22: shareholders equity requirement", target: "22: requirement unless", fill: "#808000"},
{source: "22: requirement unless", target: "22: shareholders equity through", fill: "#808000"},
{source: "22: comply with", target: "23: compliance with", fill: "#100c08"},
{source: "23: compliance with", target: "23: market capitalization requirement", fill: "#100c08"},
{source: "23: compliance with", target: "35: illustrations", fill: "#e6be8a"},
{source: "35: illustrations", target: "35: potential impediments", fill: "#e6be8a"},
{source: "35: potential impediments", target: "35: successfully", fill: "#e6be8a"},
{source: "35: successfully", target: "35: current trading price", fill: "#e6be8a"},
{source: "35: current trading price", target: "35: adversely", fill: "#e6be8a"},
{source: "35: adversely", target: "35: raise funds through", fill: "#e6be8a"},
{source: "35: raise funds through", target: "35: may raise privately", fill: "#e6be8a"},
{source: "35: may raise privately", target: "35: shareholder vote", fill: "#e6be8a"},
{source: "35: shareholder vote", target: "35: capital on", fill: "#e6be8a"},
{source: "35: capital on", target: "35: timely basis with", fill: "#e6be8a"},
{source: "35: timely basis with", target: "35: must submit such", fill: "#e6be8a"},
{source: "35: must submit such", target: "35: transaction", fill: "#e6be8a"},
{source: "35: transaction", target: "35: shareholders", fill: "#e6be8a"},
{source: "35: shareholders", target: "35: Nasdaq Capital Market ", fill: "#e6be8a"},
{source: "35: Nasdaq Capital Market ", target: "35: may materially", fill: "#e6be8a"},
{source: "35: may materially", target: "35: adversely affect", fill: "#e6be8a"},
{source: "35: adversely affect", target: "35: factors such as reduced liquidity", fill: "#e6be8a"},
{source: "35: factors such as reduced liquidity", target: "35: requirement", fill: "#e6be8a"},
{source: "35: requirement", target: "35: comply with", fill: "#e6be8a"},
{source: "35: comply with", target: "35: securities laws", fill: "#e6be8a"},
{source: "35: securities laws", target: "35: compliance with", fill: "#e6be8a"},
{source: "35: compliance with", target: "35: requirements", fill: "#e6be8a"},
{source: "35: requirements", target: "35: additional equity financing", fill: "#e6be8a"},
{source: "35: additional equity financing", target: "35: negatively impacted", fill: "#e6be8a"},
{source: "35: negatively impacted", target: "35: Contents ", fill: "#e6be8a"},
{source: "35: Contents ", target: "35: research programs", fill: "#e6be8a"},
{source: "35: research programs", target: "35: early stage there", fill: "#e6be8a"},
{source: "35: early stage there", target: "35: opportunities", fill: "#e6be8a"},
{source: "35: opportunities", target: "35: enter into collaborations with", fill: "#e6be8a"},
{source: "35: enter into collaborations with", target: "35: generally smaller", fill: "#e6be8a"},
{source: "35: generally smaller", target: "35: further from potential", fill: "#e6be8a"},
{source: "35: further from potential", target: "35: marketability", fill: "#e6be8a"},
{source: "35: marketability", target: "35: biotechnology research", fill: "#e6be8a"},
{source: "35: biotechnology research", target: "35: development", fill: "#e6be8a"},
{source: "35: development", target: "35: discussions with", fill: "#e6be8a"},
{source: "35: discussions with", target: "35: Food and Drug Administration ", fill: "#e6be8a"},
{source: "35: Food and Drug Administration ", target: "35: Phase III ", fill: "#e6be8a"},
{source: "35: Phase III ", target: "35: and the Company ", fill: "#e6be8a"},
{source: "35: illustrations", target: "38: clinical trial", fill: "#318ce7"},
{source: "38: clinical trial", target: "38: drug candidate", fill: "#318ce7"},
{source: "38: drug candidate", target: "38: erythematosus", fill: "#318ce7"},
{source: "38: erythematosus", target: "38: substantially", fill: "#318ce7"},
{source: "38: substantially", target: "38: decreasing", fill: "#318ce7"},
{source: "38: decreasing", target: "38: probability", fill: "#318ce7"},
{source: "38: probability", target: "38: diminishing", fill: "#318ce7"},
{source: "38: clinical trial", target: "56: Creation ", fill: "#0cc"},
{source: "56: Creation ", target: "56: sophisticated", fill: "#0cc"},
{source: "56: sophisticated", target: "56: expensive lab equipment", fill: "#0cc"},
{source: "56: expensive lab equipment", target: "56: facilities", fill: "#0cc"},
{source: "56: facilities", target: "56: scientists with advanced scientific knowledge", fill: "#0cc"},
{source: "56: scientists with advanced scientific knowledge", target: "56: disciplines", fill: "#0cc"},
{source: "56: disciplines", target: "56: such as chemistry biochemistry", fill: "#0cc"},
{source: "56: Creation ", target: "86: depend on", fill: "#5218fa"},
{source: "86: depend on", target: "86: hepatitis", fill: "#5218fa"},
{source: "86: hepatitis", target: "86: infections", fill: "#5218fa"},
{source: "86: infections", target: "86: conduct preclinical", fill: "#5218fa"},
{source: "86: conduct preclinical", target: "86: clinical development", fill: "#5218fa"},
{source: "86: clinical development", target: "86: regulatory approval", fill: "#5218fa"},
{source: "86: regulatory approval", target: "86: manufacture", fill: "#5218fa"},
{source: "86: manufacture", target: "86: commercialize", fill: "#5218fa"},
{source: "86: depend on", target: "START_HERE", fill: "#5218fa"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Environmental Services</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Policy</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Threaten</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Riot</td>
    </tr>
    <tr>
      <td>Natural disaster</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Prasterone">Prasterone</a></td>
      <td>Prasterone, also known as dehydroepiandrosterone (DHEA) and sold under the brand names Intrarosa, Diandrone, and Gynodian Depot among others, is a medication as well as over-the-counter dietary supplement which is used to correct DHEA deficiency due to adrenal insufficiency or old age, as a component of menopausal hormone therapy, to treat painful sexual intercourse due to vaginal atrophy, and to prepare the cervix for childbirth, among other uses. It is taken by mouth, by application to the skin, in through the vagina, or by injection into muscle.Side effects of prasterone in women include symptoms of masculinization like oily skin, acne, increased hair growth, voice changes, and increased sexual desire, headaches, insomnia, and others.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/GeneLab">GeneLab</a></td>
      <td>GeneLab is an open-access, collaborative analysis platform for space bioscience research. GeneLab aims to maximize the research resulting from experiments aboard the International Space Station (ISS) by collecting and providing access to data from genomic, transcriptomic, proteomic, and metabolomics studies aboard ISS. The Space Biosciences Division at NASA's Ames Research Center runs GeneLab.The GeneLab project is both a science collaboration initiative to maximize the omics data collected from spaceflight and from ground simulations of microgravity and radiation experiments; and a data system effort to establish a public bioinformatics repository and collaborative analysis platform for these data.GeneLab houses data from spaceflight experiments and related ground-based studies conducted on a variety of organisms including: mouse, plants, fruit fly, cultured cells, nematodes, bacteria and fungi.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Seaport_Centre">Seaport Centre</a></td>
      <td>Seaport Centre is a high-tech business park located in Redwood City, California, United States, and as of 2007 is one of the largest biotechnology research complexes in the San Francisco Bay Area.\nThe property consists of 623,000 square feet (57,900 m2) of developed building area, and is situated in proximity to the Port of Redwood City.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sarah_Wyatt">Sarah Wyatt</a></td>
      <td>Sarah Wyatt is an American, plant molecular biologist. She is a Professor in the Department of Environmental and Plant Biology at Ohio University, as well as director of the Ohio University Interdisciplinary Graduate Program in Molecular and Cellular Biology.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Shareholder">Shareholder</a></td>
      <td>A shareholder (in the United States often referred to as stockholder) of a corporation is an individual or legal entity (such as another corporation, a body politic, a trust or partnership) that is registered by the corporation as the legal owner of shares of the share capital of a public or private corporation. Shareholders may be referred to as members of a corporation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Equity_(finance)">Equity (finance)</a></td>
      <td>In finance, equity is ownership of assets that may have debts or other liabilities attached to them. Equity is measured for accounting purposes by subtracting liabilities from the value of the assets.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Shareholders'_agreement">Shareholders' agreement</a></td>
      <td>A shareholders' agreement (sometimes referred to in the U.S. as a stockholders' agreement) (SHA) is an agreement amongst the shareholders or members of a company. In practical effect, it is analogous to a partnership agreement.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Shareholder_loan">Shareholder loan</a></td>
      <td>Shareholder loan is a debt-like form of financing provided by shareholders. Usually, it is the most junior debt in the company's debt portfolio.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Desperate_Shareholders">Desperate Shareholders</a></td>
      <td>Desperate Shareholders (Russian: Отчаянные дольщики, romanized: Otchayannye dolshchiki) is a 2022 Russian crime comedy film directed by Ilya Farfell. The film produced by Yellow, Black and White also starred Maksim Lagashkin, Mikhail Trukhin, Ekaterina Stulova, Nikita Kologrivyy, and Olga Venikova.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Activist_shareholder">Activist shareholder</a></td>
      <td>An activist shareholder is a shareholder who uses an equity stake in a corporation to put pressure on its management. A fairly small stake (less than 10% of outstanding shares) may be enough to launch a successful campaign.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Annual_general_meeting">Annual general meeting</a></td>
      <td>An annual general meeting (AGM, also known as the annual meeting) is a meeting of the general membership of an organization.\nThese organizations include membership associations and companies with shareholders.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Shareholder_oppression">Shareholder oppression</a></td>
      <td>Shareholder oppression occurs when the majority shareholders in a corporation take action that unfairly prejudices the minority.  It most commonly occurs in non-publicly traded companies, because the lack of a public market for shares leaves minority shareholders particularly vulnerable, since minority shareholders cannot escape mistreatment by selling their stock and exiting the corporation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Operation_Mincemeat">Operation Mincemeat</a></td>
      <td>Operation Mincemeat was a successful British deception operation of the Second World War to disguise the 1943 Allied invasion of Sicily. Two members of British intelligence obtained the body of Glyndwr Michael, a tramp who died from eating rat poison, dressed him as an officer of the Royal Marines and placed personal items on him identifying him as the fictitious Captain (Acting Major) William Martin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bitwise_operation">Bitwise operation</a></td>
      <td>In computer programming, a bitwise operation operates on a bit string, a bit array or a binary numeral (considered as a bit string) at the level of its individual bits. It is a fast and simple action, basic to the higher-level arithmetic operations and directly supported by the processor.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Collaboration">Collaboration</a></td>
      <td>Collaboration (from Latin com- "with" + laborare "to labor", "to work") is the process of two or more people, entities or organizations working together to complete a task or achieve a goal. Collaboration is similar to cooperation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Hepatitis">Hepatitis</a></td>
      <td>Hepatitis is inflammation of the liver tissue. Some people or animals with hepatitis have no symptoms, whereas others develop yellow discoloration of the skin and whites of the eyes (jaundice), poor appetite, vomiting, tiredness, abdominal pain, and diarrhea.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Hepatitis_A">Hepatitis A</a></td>
      <td>Hepatitis A is an infectious disease of the liver caused by Hepatovirus A (HAV); it is a type of viral hepatitis. Many cases have few or no symptoms, especially in the young.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Viral_hepatitis">Viral hepatitis</a></td>
      <td>Viral hepatitis is liver inflammation due to a viral infection. It may present in acute form as a recent infection with relatively rapid onset, or in chronic form.The most common causes of viral hepatitis are the five unrelated hepatotropic viruses hepatitis A, B, C, D, and E. Other viruses can also cause liver inflammation, including cytomegalovirus, Epstein–Barr virus, and yellow fever.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Compliance_Week">Compliance Week</a></td>
      <td>Compliance Week, published by Wilmington plc, is the leading news, analysis and information resource for the ethics, governance, risk, and compliance professions. Products include weekly electronic newsletters, a bimonthly print magazine, proprietary databases and tools, events, jobs, and a variety of interactive features and forums.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Malicious_compliance">Malicious compliance</a></td>
      <td>Malicious compliance (also known as  malicious obedience) is the behavior of intentionally inflicting harm by strictly following the orders of a superior while knowing or intending that compliance with the orders will have an unintended or negative result. The term usually implies the following of an order in such a way that ignores or otherwise undermines the order's intent but follows it to the letter.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Risk_and_compliance">Risk and compliance</a></td>
      <td>Governance, risk management and compliance (GRC) is the term covering an organization's approach across these three practices: governance, risk management, and compliance. The first scholarly research on GRC was published in 2007 by Scott L. Mitchell, Founder and Chair of OCEG where GRC was formally defined as "the integrated collection of capabilities that enable an organization to reliably achieve objectives, address uncertainty and act with integrity." The research referred to common "keep the company on track" activities conducted in departments such as internal audit, compliance, risk, legal, finance, IT, HR as well as the lines of business, executive suite and the board itself.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Success">Success</a></td>
      <td>Success is the state or condition of meeting a defined range of expectations. It may be viewed as the opposite of failure.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Successful_Pyrate">The Successful Pyrate</a></td>
      <td>The Successful Pyrate is a play by Charles Johnson, first performed 1712, published 1713, dealing with the life of the pirate Henry Avery. It opened at the Theatre Royal, Drury Lane on 7 November 1712 and ran for five evenings.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/A_Successful_Man">A Successful Man</a></td>
      <td>A Successful Man (Spanish: Un hombre de éxito) is a 1986 Cuban drama film directed by Humberto Solás. It was screened in the Un Certain Regard section at the 1987 Cannes Film Festival and it was entered into the 15th Moscow International Film Festival.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/List_of_most_successful_German_U-boats">List of most successful German U-boats</a></td>
      <td>List of successful U-boats contains lists of the most successful German U-boats in the two World Wars based on total tonnage.\n\n\n== World War I ==\nThis list contains the 5 most successful German U-boats during the First World War based on total tonnage.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Kernes_Bloc_—_Successful_Kharkiv">Kernes Bloc — Successful Kharkiv</a></td>
      <td>Kernes Bloc — Successful Kharkiv (Ukrainian: Блок Кернеса — Успішний Харків, romanized: Blok Kernesa — Uspishnyy Kharkiv) is a political party of Ukraine, registered on April 12, 2016. The founder and first head of the political party was Hennadiy Kernes, who created it with the aim of participating in local elections in the Kharkiv Oblast, both in the City Council and in the Oblast Council.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trial">Clinical trial</a></td>
      <td>Clinical trials are experiments or observations done in clinical research. Such prospective biomedical or behavioral research studies on human participants are designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, dietary choices, dietary supplements, and medical devices) and known interventions that warrant further study and comparison.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Randomized_controlled_trial">Randomized controlled trial</a></td>
      <td>A randomized controlled trial (or randomized control trial; RCT) is a form of scientific experiment used to control factors not under direct experimental control. Examples of RCTs are clinical trials that compare the effects of drugs, surgical techniques, medical devices, diagnostic procedures or other medical treatments.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/ClinicalTrials.gov">ClinicalTrials.gov</a></td>
      <td>ClinicalTrials.gov is a registry of clinical trials. It is run by the United States National Library of Medicine (NLM) at the National Institutes of Health, and is the largest clinical trials database, holding registrations from over 329,000 trials from 209 countries.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pragmatic_clinical_trial">Pragmatic clinical trial</a></td>
      <td>A pragmatic clinical trial (PCT), sometimes called a practical clinical trial (PCT), is a clinical trial that focuses on correlation between treatments and outcomes in real-world health system practice rather than focusing on proving causative explanations for outcomes, which requires extensive deconfounding with inclusion and exclusion criteria so strict that they risk rendering the trial results irrelevant to much of real-world practice.\n\n\n== Examples ==\nA typical example is that an anti-diabetic medication in the real world will often be used in people with (latent or apparent) diabetes-induced kidney problems, but if a study of its efficacy and safety excluded some subsets of people with kidney problems (to escape confounding), the study's results may not reflect well what will actually happen in broad practice.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Academic_clinical_trial">Academic clinical trial</a></td>
      <td>An academic clinical trial is a clinical trial not funded by pharmaceutical or biotechnology company for commercial ends but by public-good agencies (usually universities or medical trusts) to advance medicine.  These trials are a valuable component of the health care system; they benefit patients and help determine the safety and efficacy of drugs and devices, and play an important role in the checks and balances that regular commercially oriented clinical trials.A typical area of academic clinical trials is the advancement and optimization of already existing therapies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Preregistration_(science)">Preregistration (science)</a></td>
      <td>Preregistration is the practice of registering the hypotheses, methods, and/or analyses of a scientific study before it is conducted. This can include analyzing primary data or secondary data.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/NASA_facilities">NASA facilities</a></td>
      <td>There are NASA facilities across the United States and around the world. NASA Headquarters in Washington, DC provides overall guidance and political leadership to the agency.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>GENELABS TECHNOLOGIES INC /CA      Item 1A   <font color="blue">Risk Factors </font>      There are a number of <font color="blue">risk factors</font> that should be considered by Genelabs’     <font color="blue">shareholders</font>   and  prospective  investors</td>
    </tr>
    <tr>
      <td>It  is  not  possible  to     <font color="blue">comprehensively address</font> all risks that exist, but the <font color="blue">following risks</font> in     <font color="blue">particular should</font> be considered, in addition to other information in this     <font color="blue">Annual Report </font>on Form 10-K       Risks Related to <font color="blue"><font color="blue"><font color="blue">Genelabs </font> </font>   </font>  We will need to <font color="blue"><font color="blue">raise <font color="blue">additional</font> capital</font> within</font> the <font color="blue">next several months</font>, and     if we are unable to <font color="blue">timely secure adequate funds on</font> acceptable terms, we     will be required to cease our <font color="blue">operations</font> and will not be able to <font color="blue">continue as</font>     a going concern</td>
    </tr>
    <tr>
      <td>On  March 15,  2006,  <font color="blue"><font color="blue">Genelabs </font> </font>had cash and <font color="blue">cash equivalents totaling</font>     <font color="blue">approximately</font> dlra8dtta3 million, which we presently estimate can sustain our     existing <font color="blue">operations</font> only until the beginning of the <font color="blue">fourth quarter</font> of 2006</td>
    </tr>
    <tr>
      <td>We will need to <font color="blue">raise <font color="blue">additional</font> capital</font> in order to execute our business     plans, <font color="blue">provide adequate</font> working capital to satisfy our <font color="blue"><font color="blue">obligation</font>s</font> and     continue  as  a  going concern</td>
    </tr>
    <tr>
      <td>While we are in the process of seeking     <font color="blue">additional</font>  funds, including <font color="blue">entering into</font> a <font color="blue">new <font color="blue">collaboration</font></font> for our     <font color="blue">hepatitis</font> C virus drug discovery program, selling equity, renegotiating an     existing corporate <font color="blue">collaboration</font>, and/or other <font color="blue">arrangements</font>, it is possible     that none of these efforts to seek <font color="blue">additional</font> funds will be successful</td>
    </tr>
    <tr>
      <td>If     these efforts are not successful we will need to terminate <font color="blue">operations</font> and     you may lose your <font color="blue">entire <font color="blue">investment</font></font></td>
    </tr>
    <tr>
      <td>If one or more of these efforts are     successful, the amount of funds we <font color="blue">raise may still</font> not be sufficient for us     to sustain <font color="blue">operations</font> as planned or at all</td>
    </tr>
    <tr>
      <td>As of the date of this filing,     there is substantial <font color="blue">doubt about</font> the Company’s ability to <font color="blue">continue as</font> a     going concern due to its <font color="blue">historical negative cash flow</font> and because the     Company does not currently have <font color="blue">sufficient committed capital</font> to meet its     projected operating needs for at least the <font color="blue">next twelve months</font></td>
    </tr>
    <tr>
      <td>Additionally,     our  <font color="blue"><font color="blue">financial condition</font> may lead</font> our vendors and suppliers to require     <font color="blue">advance payments</font> or security deposits, further draining our resources, and     may result in loss of some of our employees who <font color="blue">seek employment elsewhere</font></td>
    </tr>
    <tr>
      <td>If we raise <font color="blue">additional</font> funds through the issuance of equity, or securities     <font color="blue">convertible into equity</font>, we may be required to do so at a price per share     below  then-current  trading  prices,  thereby  diluting  our  current     <font color="blue">shareholders</font></td>
    </tr>
    <tr>
      <td>11       _________________________________________________________________    [53]Table of <font color="blue">Contents       </font>We may not be able to obtain <font color="blue">additional</font> funds on acceptable terms, or at     all</td>
    </tr>
    <tr>
      <td>Other  sources  of capital, such as a <font color="blue">collaboration</font> or strategic     alliance, may require us to <font color="blue">grant <font color="blue">third parties</font> rights</font> to our <font color="blue">intellectual</font>     <font color="blue">property assets</font>, or require us to <font color="blue"><font color="blue">adversely</font> renegotiate</font> the terms of one or     more  of  our  existing <font color="blue">collaboration</font>s</td>
    </tr>
    <tr>
      <td>Although we are <font color="blue">currently discussing with <font color="blue">third parties</font></font> a     <font color="blue">collaboration</font> for our HCV non-nucleoside drug discovery program, we may fail     to <font color="blue">enter into</font> any <font color="blue">agreement on</font> acceptable terms, if at all</td>
    </tr>
    <tr>
      <td>We also may be     unable to <font color="blue">find buyers willing</font> to purchase our equity or to license other     products  or <font color="blue">technology on commercially</font> favorable terms, if at all</td>
    </tr>
    <tr>
      <td>If     <font color="blue">additional</font> funds are not available we may be required to cease <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>In order to maintain its license to <font color="blue">use <font color="blue">radioactive</font> research materials</font>,     <font color="blue">Genelabs </font>has established a dlra150cmam000 standby letter of credit in favor of the     Radiologic Health Branch of the <font color="blue">California </font>Department of Health Services</td>
    </tr>
    <tr>
      <td>If     we  our  unable to raise <font color="blue">additional</font> funds, the letter of credit may be     terminated  and  the <font color="blue"><font color="blue">radioactive</font> materials license may</font> be suspended or     revoked</td>
    </tr>
    <tr>
      <td>Because we may not continue to qualify for <font color="blue">listing on</font> the Nasdaq quotation     system, the value of your <font color="blue">investment</font> in <font color="blue">Genelabs </font><font color="blue">may <font color="blue">substantially</font> decrease</font></td>
    </tr>
    <tr>
      <td>To  remain  listed  on the <font color="blue"><font color="blue">Nasdaq Capital Market</font> </font>we must have at least     dlra2dtta5 million  in  <font color="blue">shareholders</font>’  equity  or a <font color="blue">market value</font> of at least     dlra35 million</td>
    </tr>
    <tr>
      <td>Our  <font color="blue">shareholders</font>’  equity  as  of <font color="blue">December </font>31, 2005 was     dlra2dtta3 million  and  as of March 15, 2006 the Company’s <font color="blue">market value</font> was     <font color="blue">approximately</font> dlra34 million</td>
    </tr>
    <tr>
      <td>We currently do not <font color="blue">comply with</font> the minimum     shareholder’s equity <font color="blue">requirement</font>, and will not be able to <font color="blue">comply with</font> this     <font color="blue"><font color="blue">requirement</font> unless</font> we are able to increase our <font color="blue">shareholders</font>’ equity through     a financing or other means</td>
    </tr>
    <tr>
      <td>We may not be able to maintain <font color="blue">compliance with</font>     the <font color="blue">market capitalization <font color="blue">requirement</font></font></td>
    </tr>
    <tr>
      <td>To <font color="blue">remain listed on</font> the <font color="blue"><font color="blue">Nasdaq Capital Market</font> </font>the closing bid price of our     stock must be at least dlra1dtta00 per share</td>
    </tr>
    <tr>
      <td>We may not be able to maintain     <font color="blue">compliance with</font> the minimum closing <font color="blue">bid price <font color="blue">requirement</font></font></td>
    </tr>
    <tr>
      <td>If <font color="blue">Genelabs </font>is unable to meet or maintain <font color="blue">compliance with</font> all of the <font color="blue">Nasdaq     </font><font color="blue">listing <font color="blue"><font color="blue">requirement</font>s</font></font>, it will be <font color="blue">delisted from</font> the <font color="blue">Nasdaq Capital Market</font></td>
    </tr>
    <tr>
      <td>If     <font color="blue">delisted from</font> the <font color="blue">Nasdaq Capital Market</font>, <font color="blue">Genelabs </font><font color="blue">might apply</font> for <font color="blue">listing on</font>     the <font color="blue">American Stock Exchange</font></td>
    </tr>
    <tr>
      <td><font color="blue">Genelabs </font>may fail to meet the <font color="blue"><font color="blue">requirement</font>s</font> for     initial  listing or may fail to maintain <font color="blue">compliance with</font> the continued     <font color="blue">listing <font color="blue"><font color="blue">requirement</font>s</font></font> of the <font color="blue">American Stock Exchange</font></td>
    </tr>
    <tr>
      <td><font color="blue">Delisting </font>from the     <font color="blue"><font color="blue">Nasdaq Capital Market</font> </font><font color="blue">would <font color="blue">adversely</font> affect</font> the <font color="blue">trading price</font> of our common     stock, <font color="blue"><font color="blue">significant</font>ly</font> limit the liquidity of our <font color="blue">common stock</font> and impair our     ability to raise <font color="blue">additional</font> funds</td>
    </tr>
    <tr>
      <td>We may not be profitable in the near future or at all and in order to carry     out our business plans we will require <font color="blue">additional</font> funds which may not be     available</td>
    </tr>
    <tr>
      <td>We have incurred losses each year since our inception and have <font color="blue">accumulated</font>     <font color="blue">approximately</font>  dlra229 million  in  net losses through <font color="blue">December </font>31, 2005,     including a net loss of dlra10dtta8 million for the year ended <font color="blue">December </font>31, 2005</td>
    </tr>
    <tr>
      <td>We may never be profitable and our <font color="blue">revenues may never</font> be sufficient to fund     <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We presently estimate that our <font color="blue">current cash resources</font> are adequate to fund     our current <font color="blue">operations</font> to <font color="blue">approximately</font> the beginning of the <font color="blue">fourth quarter</font>     of 2006</td>
    </tr>
    <tr>
      <td>We will require <font color="blue">additional</font> capital to carry out our business plans</td>
    </tr>
    <tr>
      <td>The following are <font color="blue">illustrations</font> of <font color="blue">potential impediments</font> to our ability to     <font color="blue">successfully</font> secure sufficient <font color="blue">additional</font> funds:         •  the current <font color="blue">trading price</font> of our stock will materially and <font color="blue">adversely</font>     affect our ability to <font color="blue">raise funds through</font> the issuance of stock;         •  the amount of stock we may sell and capital we <font color="blue">may raise privately</font>     without  a <font color="blue">shareholder vote</font> is limited, and we may be unable to secure     <font color="blue">capital on</font> a <font color="blue">timely basis with</font> acceptable terms if we <font color="blue">must submit such</font> a     <font color="blue">transaction</font> to our <font color="blue">shareholders</font> for approval;         •  the listing of our stock on the <font color="blue"><font color="blue">Nasdaq Capital Market</font> </font><font color="blue">may materially</font>     and <font color="blue">adversely</font> affect our ability to <font color="blue">raise funds through</font> the issuance of     stock because of <font color="blue">factors such as reduced liquidity</font> and the <font color="blue">requirement</font> to     <font color="blue">comply with</font> state <font color="blue">securities laws</font>;         •  if we are unable to maintain <font color="blue">compliance with</font> the Nasdaq’s listing     <font color="blue"><font color="blue">requirement</font>s</font>, our ability to <font color="blue">successfully</font> obtain <font color="blue">additional</font> equity financing     will be <font color="blue">negatively impacted</font>;                                         12       _________________________________________________________________    [54]Table of <font color="blue">Contents       </font>    •  since our <font color="blue">research programs</font> are in an <font color="blue">early stage</font>, there are fewer     <font color="blue">opportunities</font> to <font color="blue">enter into</font> <font color="blue">collaboration</font>s with other companies and up-front     payments for early-stage <font color="blue"><font color="blue">pharmaceutical</font> research</font> <font color="blue">collaboration</font>s are     <font color="blue">generally smaller</font> for projects that are <font color="blue">further from potential</font>     <font color="blue">marketability</font>;         •  <font color="blue">biotechnology research</font> and <font color="blue">development</font> projects have a high risk of     failure and the failure of our research-stage <font color="blue">drug candidate</font>s or those of     other companies could discourage funding sources from providing us with     financing; and         •  <font color="blue">discussions with</font> the <font color="blue">Food and Drug Administration </font>have indicated that     the Company will need to conduct at least one <font color="blue">additional</font> <font color="blue">Phase III </font>clinical     trial <font color="blue">of Prestara </font>in order to qualify for approval, <font color="blue">and the Company </font>does not     have the funds to conduct the trial</td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font>funds for our research and <font color="blue">development</font> <font color="blue">activities</font> may not be     <font color="blue">available on</font> acceptable terms, if at all</td>
    </tr>
    <tr>
      <td>The <font color="blue">un<font color="blue">availability</font></font> of <font color="blue">additional</font>     <font color="blue">funds could delay</font> or prevent the <font color="blue">development</font> of some or all of our products     and  <font color="blue">technologies</font>,  which  would have a material adverse effect on our     business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The results of our <font color="blue">clinical trial</font> of Prestara^tm, Genelabs’ <font color="blue">drug candidate</font>     for  systemic  lupus  <font color="blue">erythematosus</font>,  were not positive, <font color="blue">substantially</font>     <font color="blue">decreasing</font> the <font color="blue">probability</font> that Prestara will ever be approved for marketing     and <font color="blue">diminishing</font> our business prospects</td>
    </tr>
    <tr>
      <td>In order to <font color="blue">satisfy conditions set by</font> the US Food and Drug Administration,     or FDA, we conducted a <font color="blue">Phase III </font><font color="blue">clinical trial</font> <font color="blue">of Prestara </font><font color="blue">on women with</font>     lupus taking <font color="blue">glucocorticoids using</font> BMD as the trial’s <font color="blue">primary endpoint</font></td>
    </tr>
    <tr>
      <td><font color="blue">Prestara  </font>is  a  <font color="blue">pharmaceutical</font> formulation containing highly purified     prasterone, the <font color="blue">synthetic equivalent</font> of <font color="blue">dehydroepiandrosterone</font> or DHEA, a     naturally occurring hormone</td>
    </tr>
    <tr>
      <td>This <font color="blue">clinical trial</font> did not <font color="blue">demonstrate</font> a     <font color="blue">statistically <font color="blue">significant</font> difference between</font> the <font color="blue">bone mineral density</font> of the     group  of  patients  taking  <font color="blue">Prestara  </font>and  the  group taking placebo</td>
    </tr>
    <tr>
      <td>Additionally, the trial was not powered to <font color="blue">demonstrate</font>, and in fact did not     <font color="blue">demonstrate</font>, a <font color="blue">statistically <font color="blue">significant</font> benefit</font> in <font color="blue">secondary endpoints such</font>     <font color="blue">as amelioration</font> of <font color="blue">lupus symptoms</font></td>
    </tr>
    <tr>
      <td>While we believe we have identified most     probable causes for the failure of this study to reach its <font color="blue">primary endpoint</font>,     we may never know <font color="blue">with certainty</font> what the cause or causes of this failure     were</td>
    </tr>
    <tr>
      <td>A <font color="blue">clinical trial</font> of prasterone (the active ingredient in Prestara) was     <font color="blue">conducted by</font> Genovate Biotechnology Co, Ltd, or Genovate, a Taiwan-based     company that has a <font color="blue"><font color="blue">license from</font> us</font> for Prestara in most Asian countries</td>
    </tr>
    <tr>
      <td>In     April 2005 we announced that this <font color="blue">clinical trial</font> did not meet its primary     endpoint, <font color="blue">bone mineral density</font> at the <font color="blue">lumbar spine</font></td>
    </tr>
    <tr>
      <td>Because both our and     Genovate’s <font color="blue">clinical trial</font>s did not meet their <font color="blue">primary endpoint</font>s, the FDA     will not approve Prestara without another <font color="blue">Phase III </font><font color="blue">clinical trial</font></td>
    </tr>
    <tr>
      <td>It may     not be possible to design and implement a trial that would <font color="blue">successfully</font>     provide results sufficient to obtain FDA approval for Prestara, and <font color="blue"><font color="blue"><font color="blue">Genelabs </font> </font>   </font>currently does not have the funds to <font color="blue">conduct such</font> a trial</td>
    </tr>
    <tr>
      <td>Our <font color="blue">research programs</font> are in an <font color="blue">early stage</font> and may not <font color="blue">successfully</font> produce     <font color="blue">commercial products</font></td>
    </tr>
    <tr>
      <td><font color="blue">Pharmaceutical </font><font color="blue">discovery research</font> is inherently high-risk because of the     <font color="blue">high failure rate</font> of projects</td>
    </tr>
    <tr>
      <td>To date, our <font color="blue"><font color="blue">pharmaceutical</font> research</font> has been     <font color="blue">focused on</font> a limited number of targets for which no or <font color="blue">few commercial drugs</font>     have been <font color="blue">successfully</font> developed</td>
    </tr>
    <tr>
      <td>Our projects may fail if, among other     reasons, the compounds being developed fail to <font color="blue">meet criteria</font> for potency,     toxicity,  <font color="blue">pharmacokinetics</font>,  manufacturability, <font color="blue">intellectual</font> property     protection and <font color="blue">freedom from infringement</font>, or other criteria; if others     develop <font color="blue">competing therapies</font>; or if we fail to make progress due to lack of     resources or access to enabling <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>Genelabs’ <font color="blue"><font color="blue">product candidate</font>s</font>,     other than Prestara, are in an <font color="blue">early stage</font> of research</td>
    </tr>
    <tr>
      <td>If <font color="blue">Genelabs </font><font color="blue">discovers compounds</font> that have the potential to be drugs, public     information about our <font color="blue">research success may lead</font> other <font color="blue">companies with greater</font>     resources to focus more efforts in areas similar to ours</td>
    </tr>
    <tr>
      <td><font color="blue">Genelabs </font>has     limited human and <font color="blue">financial resources</font></td>
    </tr>
    <tr>
      <td><font color="blue">Creation </font>of the type of compounds we     seek to discover requires <font color="blue">sophisticated</font> and <font color="blue">expensive lab equipment</font> and     <font color="blue">facilities</font>, a team of <font color="blue">scientists with advanced scientific knowledge</font> in many     <font color="blue">disciplines</font>  such as chemistry, biochemistry and biology, and time and     effort</td>
    </tr>
    <tr>
      <td>Large <font color="blue"><font color="blue">pharmaceutical</font> companies</font> have access to the <font color="blue">latest equipment</font>     and  have many more <font color="blue">personnel available</font> to <font color="blue">focus on solving particular</font>     research                                         13       _________________________________________________________________    [55]Table of <font color="blue">Contents       </font>problems, including those that <font color="blue">Genelabs </font>is <font color="blue">investigating</font></td>
    </tr>
    <tr>
      <td>Therefore, even if     our  research  programs  are  successful,  we  may  have a <font color="blue">competitive</font>     <font color="blue">disadvantage</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">collaboration</font>s may fail</td>
    </tr>
    <tr>
      <td>We have entered into <font color="blue">collaboration</font>s with Gilead, GSK, Watson, Tanabe and     other companies and we may <font color="blue">enter into</font> future <font color="blue">collaboration</font>s with these or     other  companies</td>
    </tr>
    <tr>
      <td>Our <font color="blue"><font color="blue">collaborator</font>s may</font> breach their contracts, or our     <font color="blue"><font color="blue">collaborator</font>s may</font> not <font color="blue">diligently</font> and <font color="blue">successfully</font> develop and <font color="blue">commercialize</font>     the results of the research</td>
    </tr>
    <tr>
      <td>Alternatively, our <font color="blue"><font color="blue">collaborator</font>s may</font> elect not     to extend or augment the <font color="blue">collaboration</font>s</td>
    </tr>
    <tr>
      <td>In this regard, Gilead may not     continue to fund our <font color="blue">research beyond</font> its <font color="blue">obligation</font> in the <font color="blue">research contract</font>     and  GSK may choose not to continue developing the HEV vaccine</td>
    </tr>
    <tr>
      <td>We are     <font color="blue">dependent on</font> our <font color="blue">collaborator</font>s to <font color="blue">successfully</font> carry <font color="blue">out preclinical</font> and     clinical <font color="blue">development</font>, to obtain <font color="blue">regulatory</font> approvals, and/or to market and     sell any products arising from the research and/or <font color="blue">development</font> <font color="blue">conducted by</font>     the company or the <font color="blue">collaborator</font></td>
    </tr>
    <tr>
      <td>Factors which may cause our <font color="blue">collaborator</font>s     to fail in these efforts include: problems with toxicity, bio<font color="blue">availability</font> or     efficacy of the <font color="blue">product candidate</font>, <font color="blue">difficult</font>ies in <font color="blue">manufacture</font>, problems in     satisfying  <font color="blue">regulatory</font>  <font color="blue"><font color="blue">requirement</font>s</font>, emergence of <font color="blue">competitive</font> product     <font color="blue">candidates</font>  developed  by  the <font color="blue">collaborator</font> or by others, insufficient     commercial opportunity, problems the <font color="blue"><font color="blue">collaborator</font>s may</font> have with their own     <font color="blue">contractors</font>, lack of <font color="blue">patent protection</font> for our <font color="blue">product candidate</font> or claims     by others that it infringes their patents or other <font color="blue">intellectual</font> property     rights</td>
    </tr>
    <tr>
      <td><font color="blue">Collaboration </font>on a project also may result in <font color="blue">disputes with</font> the     <font color="blue">collaborator</font> over the efforts of the Company and/or the <font color="blue">collaborator</font> or     rights to <font color="blue">intellectual</font> property</td>
    </tr>
    <tr>
      <td>If we are unable to obtain the funds to     ensure  the  continuance of our business or fail to perform all of our     <font color="blue"><font color="blue">obligation</font>s</font>, our <font color="blue"><font color="blue">collaborator</font>s may</font> withhold further funding, seek to seize     <font color="blue">control over</font> our <font color="blue">intellectual</font> property and other assets, and/or assert     claims  for <font color="blue">damages against us</font></td>
    </tr>
    <tr>
      <td>In the course of the <font color="blue">collaboration</font> our     <font color="blue">collaborator</font> may obtain know-how which enables it to <font color="blue">compete with us</font> in the     same area of research and/or <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>Because research and <font color="blue">development</font>     results are unpredictable, we and our <font color="blue"><font color="blue">collaborator</font>s may</font> not achieve any of     the <font color="blue">milestones</font> in the <font color="blue">collaboration</font> agreements</td>
    </tr>
    <tr>
      <td>We do not have the resources to <font color="blue">conduct preclinical</font> <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>We do not have the personnel or <font color="blue">facilities</font> to conduct the <font color="blue">formal preclinical</font>     <font color="blue">development</font> of our <font color="blue">hepatitis</font> C <font color="blue">compounds as <font color="blue">necessary</font></font> to file an <font color="blue">application</font>     to  conduct  clinical  trials  in humans</td>
    </tr>
    <tr>
      <td>Our experience in conducting     preclinical <font color="blue">development</font>, including <font color="blue">formal toxicology studies</font>, is limited</td>
    </tr>
    <tr>
      <td><font color="blue">Outsourcing </font>is expensive, time-consuming and requires <font color="blue">reliance on</font>     the performance of <font color="blue">third parties</font></td>
    </tr>
    <tr>
      <td>Because of our <font color="blue">financial condition</font>, stock     performance and setbacks in our Prestara^tm program, we may have <font color="blue"><font color="blue">difficult</font>y</font>     <font color="blue">hiring specialized personnel</font></td>
    </tr>
    <tr>
      <td>We may be unable to attract or retain <font color="blue">key personnel</font></td>
    </tr>
    <tr>
      <td>Our ability to develop our business depends in part upon our attracting and     retaining <font color="blue">qualified <font color="blue">management</font></font> and <font color="blue">scientific personnel</font></td>
    </tr>
    <tr>
      <td>As the number of     qualified personnel is limited, <font color="blue">competition</font> for such staff is intense</td>
    </tr>
    <tr>
      <td>We     may not be able to continue to attract or retain such people on acceptable     terms, given the <font color="blue">competition</font> for those with similar <font color="blue">qualifications among</font>     biotechnology, <font color="blue">pharmaceutical</font> and healthcare companies, universities and     <font color="blue">nonprofit research institutions</font></td>
    </tr>
    <tr>
      <td>Furthermore, the negative results from the     most recent <font color="blue">clinical trial</font>s of Prestara^tm and the ensuing drop in our stock     price, as well as the Company’s <font color="blue">declining cash position</font>, have <font color="blue"><font color="blue">significant</font>ly</font>     diminished our future business prospects, thus making it more <font color="blue">difficult</font> to     retain  existing  employees  and  to  <font color="blue">recruit new employees</font></td>
    </tr>
    <tr>
      <td>Since the     <font color="blue">announcement</font> of the results of our <font color="blue">Phase III </font>trial of <font color="blue">Prestara in October     </font>2004, <font color="blue">substantially</font> all of our clinical <font color="blue">development</font> staff have left the     Company</td>
    </tr>
    <tr>
      <td>The loss of our <font color="blue">key personnel</font> or the failure to recruit <font color="blue">additional</font>     <font color="blue">key personnel</font> could <font color="blue"><font color="blue">significant</font>ly</font> impede attainment of our <font color="blue">objectives</font> and     harm our <font color="blue">financial condition</font> and operating results</td>
    </tr>
    <tr>
      <td>Additionally, recent and     proposed laws, rules and <font color="blue"><font color="blue">regulations</font> increasing</font> the <font color="blue">liability</font> of <font color="blue">directors</font>     and <font color="blue">officers may</font> make it more <font color="blue">difficult</font> to retain <font color="blue">incumbents</font> and to recruit     for these positions</td>
    </tr>
    <tr>
      <td>If <font color="blue">third parties</font> on whom we rely do not perform <font color="blue">as <font color="blue">contractual</font>ly</font> required or     expected,  we  may  not  be  able to obtain <font color="blue">regulatory</font> approval for or     <font color="blue">commercialize</font> our <font color="blue"><font color="blue">product candidate</font>s</font></td>
    </tr>
    <tr>
      <td>As part of our process of conducting drug <font color="blue">discovery research</font> and clinical     trials we rely on <font color="blue">third parties</font> such as medical institutions, pre-clinical     and clinical investigators, contract laboratories and <font color="blue">contract research</font>                                         14       _________________________________________________________________    [56]Table of <font color="blue">Contents       </font><font color="blue">organizations</font> to <font color="blue">participate</font> in the conduct of our <font color="blue">clinical trial</font>s</td>
    </tr>
    <tr>
      <td>We     <font color="blue">depend on</font> Gilead for nucleoside compounds for treatment of <font color="blue">hepatitis</font> C     <font color="blue">infections</font>, and on GSK for the <font color="blue">hepatitis</font> E vaccine, to <font color="blue">conduct preclinical</font>     and clinical <font color="blue">development</font>, to obtain <font color="blue">regulatory</font> approval and to <font color="blue">manufacture</font>     and <font color="blue">commercialize</font></td>
    </tr>
    <tr>
      <td>If these <font color="blue">third parties</font> do not <font color="blue">successfully</font> carry out     their  <font color="blue">contractual</font>  duties  or <font color="blue">regulatory</font> <font color="blue"><font color="blue">obligation</font>s</font> or meet expected     <font color="blue">deadlines</font>, if the <font color="blue">third parties</font> need to be replaced or if the quality or     accuracy of the data they obtain is <font color="blue">compromised due</font> to their failure to     adhere to our <font color="blue">clinical protocols</font> or <font color="blue">regulatory</font> <font color="blue"><font color="blue">requirement</font>s</font> or for other     reasons, our preclinical <font color="blue">development</font> <font color="blue">activities</font> or <font color="blue">clinical trial</font>s may be     extended, delayed, suspended or terminated, and we may not be able to obtain     <font color="blue">regulatory</font>  approval  for  or  <font color="blue">successfully</font>  <font color="blue">commercialize</font> our product     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>If our Japanese marketing partner for Prestara^tm does not obtain approval     to market <font color="blue">Prestara in Japan</font>, our business <font color="blue">prospects will suffer</font> because we     do not have <font color="blue">capabilities</font> to develop <font color="blue">Prestara for Japan </font>ourselves and we     would lose a <font color="blue"><font color="blue">significant</font> source</font> of <font color="blue">potential revenue</font></td>
    </tr>
    <tr>
      <td>Our  licensee  in Japan, Tanabe, has not conducted <font color="blue">clinical trial</font>s for     <font color="blue">Prestara in Japan</font></td>
    </tr>
    <tr>
      <td>Given the most recent negative results in the clinical     trials <font color="blue">of Prestara </font>and the similar <font color="blue">formulation used</font> in Taiwan, Tanabe may     not proceed with <font color="blue">clinical trial</font>s, or if it does, the results from such     <font color="blue">trials may</font> not be positive</td>
    </tr>
    <tr>
      <td>Our <font color="blue">outside suppliers</font> and <font color="blue">manufacture</font>rs for Prestara^tm and our <font color="blue">hepatitis</font> C     compounds are subject to regulation, including by the FDA, and if they do     not meet their <font color="blue">commitments</font>, we would have to find substitute suppliers or     <font color="blue">manufacture</font>rs <font color="blue">which could</font> delay supply of product to the market</td>
    </tr>
    <tr>
      <td><font color="blue">Regulatory </font><font color="blue"><font color="blue">requirement</font>s</font> applicable to <font color="blue"><font color="blue"><font color="blue">pharmaceutical</font> products</font> tend</font> to make     the <font color="blue">substitution</font> of suppliers and <font color="blue">manufacture</font>rs costly and time consuming</td>
    </tr>
    <tr>
      <td>We  rely  on a single supplier of prasterone, the active ingredient in     Prestara, and we rely on a single finished product <font color="blue">manufacture</font>r, Patheon     Inc, for production <font color="blue">of Prestara </font>capsules and for packaging</td>
    </tr>
    <tr>
      <td>We rely on     another <font color="blue">manufacture</font>r for the scale up and production of our <font color="blue">hepatitis</font> C     compounds</td>
    </tr>
    <tr>
      <td>The <font color="blue">disqualification</font> of these suppliers and <font color="blue">manufacture</font>rs through     their failure to <font color="blue">comply with</font> <font color="blue">regulatory</font> <font color="blue"><font color="blue">requirement</font>s</font> could negatively impact     our  business  because of delays and costs in obtaining and qualifying     <font color="blue">alternate suppliers</font></td>
    </tr>
    <tr>
      <td>We have no internal manufacturing <font color="blue">capabilities</font> for     <font color="blue"><font color="blue">pharmaceutical</font> products</font> and are entirely <font color="blue">dependent on</font> contract <font color="blue">manufacture</font>rs     and suppliers for the <font color="blue">manufacture</font> of our <font color="blue">drug candidate</font>s</td>
    </tr>
    <tr>
      <td><font color="blue">Genelabs </font>and our     <font color="blue">North American </font><font color="blue">collaborator</font>, Watson, <font color="blue">previously</font> arranged for the <font color="blue">manufacture</font>     of quantities <font color="blue">of Prestara </font>and its active ingredient in <font color="blue">anticipation</font> of     possible  marketing  approval</td>
    </tr>
    <tr>
      <td>This inventory has exceeded its initial     <font color="blue">expiration date</font>, although the <font color="blue">expiration date</font> of the active ingredient may     be extended if it <font color="blue">successfully</font> passes re-testing</td>
    </tr>
    <tr>
      <td>The  following  could  harm our ability to <font color="blue">manufacture</font> Prestara or our     <font color="blue">hepatitis</font> C compounds:         •  the <font color="blue">un<font color="blue">availability</font></font> at reasonable prices of <font color="blue">adequate quantities</font> of the     active ingredient or <font color="blue">intermediates</font>;         •  the loss of a supplier’s or <font color="blue">manufacture</font>r’s <font color="blue">regulatory</font> approval;         •  the failure of a supplier or <font color="blue">manufacture</font>r to meet <font color="blue">regulatory</font> agency     pre-approval inspection <font color="blue"><font color="blue">requirement</font>s</font>;         •  the failure of a supplier or <font color="blue">manufacture</font>r to maintain <font color="blue">compliance with</font>     ongoing <font color="blue">regulatory</font> agency <font color="blue"><font color="blue">requirement</font>s</font>;         •  the <font color="blue">inability</font> to develop <font color="blue">alternative sources</font> in a <font color="blue">timely manner</font> or at     all;         •  <font color="blue">inability</font> or refusal of the <font color="blue">manufacture</font>rs to meet our needs for any     reason, such as loss or damage to <font color="blue">facilities</font> or <font color="blue">labor disputes</font>;         •  <font color="blue">manufacture</font> of product that is defective in any manner;         •  <font color="blue">competing demands on</font> the contract <font color="blue">manufacture</font>r’s capacity, for example,     shifting <font color="blue">manufacturing priorities</font> to their own products or more profitable     products for other customers; and         •  <font color="blue">complications</font> in the scale-up or large-scale manufacturing of our     <font color="blue">hepatitis</font> C compounds</td>
    </tr>
    <tr>
      <td>15       _________________________________________________________________    [57]Table of <font color="blue">Contents       </font>  We may be unable to obtain patents or protect our <font color="blue">intellectual</font> property     rights, or <font color="blue">others could</font> assert their <font color="blue">patents against us</font></td>
    </tr>
    <tr>
      <td>Agency or court <font color="blue">proceedings</font> could invalidate our current patents, or patents     that issue on pending <font color="blue">application</font>s</td>
    </tr>
    <tr>
      <td>Our business <font color="blue">would suffer</font> if we do not     <font color="blue">successfully</font> defend or enforce our patents, which would result in loss of     <font color="blue">proprietary protection</font> for our <font color="blue">technologies</font> and products</td>
    </tr>
    <tr>
      <td>Patent <font color="blue">litigation</font>     may be <font color="blue">necessary</font> to <font color="blue">enforce patents</font> to determine the scope and validity of     our <font color="blue">proprietary rights</font> or the <font color="blue">proprietary rights</font> of another</td>
    </tr>
    <tr>
      <td>The active ingredient in Prestara is prasterone, more <font color="blue">commonly known as</font>     <font color="blue">dehydroepiandrosterone</font>, or <font color="blue">DHEA DHEA </font>is a compound that has been in the     <font color="blue">public domain</font> for many years</td>
    </tr>
    <tr>
      <td>Although the specific polymorphic form <font color="blue">of DHEA     </font>we have used may be patentable, we do not believe it is possible to obtain     <font color="blue">patent protection</font> for the <font color="blue">base chemical compound anywhere</font> in the world</td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Genelabs </font> </font>licensed  two <font color="blue">United States </font><font color="blue">patents covering uses</font> of DHEA in     treating lupus from <font color="blue">Stanford University </font>in 1993</td>
    </tr>
    <tr>
      <td><font color="blue">The Stanford </font>patents expire     in  2012 and 2013, and the <font color="blue">license expires</font> when the patents expire</td>
    </tr>
    <tr>
      <td>In     addition, we have filed patent <font color="blue">application</font>s covering <font color="blue">additional</font> uses for     <font color="blue">Prestara  </font>and  various  <font color="blue">pharmaceutical</font> <font color="blue">formulations</font> and intend to file     <font color="blue">additional</font> <font color="blue">application</font>s as <font color="blue">appropriate</font></td>
    </tr>
    <tr>
      <td>We have filed patent <font color="blue">application</font>s     <font color="blue">covering compounds from</font> our HCV drug discovery programs; however, no patents     are <font color="blue">currently issued</font></td>
    </tr>
    <tr>
      <td>A number of patents have issued to <font color="blue">Genelabs </font>covering     our drug discovery <font color="blue">technologies</font> and methods related to <font color="blue">selective regulation</font>     of <font color="blue">gene expression</font> and the control of viral <font color="blue">infections</font></td>
    </tr>
    <tr>
      <td>A number of patent     <font color="blue">application</font>s are pending</td>
    </tr>
    <tr>
      <td>If another company <font color="blue">successfully</font> brings legal action against us claiming our     <font color="blue">activities</font> violate, or infringe, their patents, a court may require us to     pay <font color="blue">significant</font> damages and prevent us from using or selling products or     <font color="blue">technologies</font> covered by those patents</td>
    </tr>
    <tr>
      <td>Others <font color="blue">could independently</font> develop     the  same or similar <font color="blue">discoveries</font> and may have <font color="blue">priority over</font> any patent     <font color="blue">application</font>s <font color="blue">Genelabs </font>has filed on these <font color="blue">discoveries</font></td>
    </tr>
    <tr>
      <td><font color="blue">Prosecuting </font>patent     priority <font color="blue">proceedings</font> and defending <font color="blue">litigation</font> claims can be very expensive     and time-consuming for <font color="blue">management</font></td>
    </tr>
    <tr>
      <td>In addition, <font color="blue">intellectual</font> property that     is important for advancing our <font color="blue">drug discovery efforts</font> or for uses for the     active ingredient in Prestara owned <font color="blue">by others might</font> exist now or in the     future</td>
    </tr>
    <tr>
      <td>We might not be able to obtain licenses to a <font color="blue">necessary</font> product or     <font color="blue">technology on commercially</font> reasonable terms, or at all, and therefore, we     may not pursue research, <font color="blue">development</font> or <font color="blue">commercialization</font> of promising     products</td>
    </tr>
    <tr>
      <td>The lease for our <font color="blue">facilities</font> expires in November and we may not have the     <font color="blue">facilities</font> to continue our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The lease for the <font color="blue">facilities</font> housing nearly all of our <font color="blue">operations</font> expires in     November 2006</td>
    </tr>
    <tr>
      <td>If we are unable to <font color="blue">remain on</font> our     <font color="blue">current premises</font>, we may be unable to obtain alternative <font color="blue">facilities</font> due to     our <font color="blue">financial condition</font> or for other reasons, and we may be unable to fully     relocate our <font color="blue">operations</font> before <font color="blue">termination</font> of our current lease, thereby     incurring  a  <font color="blue">significant</font> <font color="blue">interruption</font> in our business <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Any     <font color="blue">relocation would</font> result in substantial <font color="blue">disruption</font> of our <font color="blue">operations</font> and     diversion of <font color="blue">management</font> and <font color="blue">staff away from</font> our core business <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>The terms for the existing or any <font color="blue">new premises may</font> require <font color="blue">higher rent</font>,     <font color="blue">advance payments</font>, deposits or other terms <font color="blue">disadvantage</font>ous to us</td>
    </tr>
    <tr>
      <td>We sublease     a portion of our premises to <font color="blue">Genitope Corp</font></td>
    </tr>
    <tr>
      <td>for <font color="blue">approximately</font> dlra150cmam000 per     year and there is no assurance that the <font color="blue">sublease will continue on</font> favorable     terms, or at all, or that we would be able to remove the <font color="blue">space from</font> any     extension of our lease</td>
    </tr>
    <tr>
      <td>Our <font color="blue">facilities</font> in <font color="blue">California </font>are located near an <font color="blue">earthquake fault</font>, and an     <font color="blue">earthquake could disrupt</font> our <font color="blue">operations</font> and <font color="blue">adversely</font> effect results</td>
    </tr>
    <tr>
      <td>Almost all of our <font color="blue">operations</font> are conducted in a <font color="blue">single <font color="blue">facility</font> built on</font>     landfill  in  an  area of <font color="blue">California </font>near <font color="blue">active geologic faults which</font>     <font color="blue">historically</font> have caused <font color="blue">major earthquakes from</font> time to time</td>
    </tr>
    <tr>
      <td>The office     park where the <font color="blue">facility</font> is located is <font color="blue">approximately</font> at sea level behind     <font color="blue">levees sheltering</font> the <font color="blue">buildings from</font> the <font color="blue">San Francisco Bay</font></td>
    </tr>
    <tr>
      <td>In the event of     a  <font color="blue">significant</font>  earthquake, we could experience <font color="blue">significant</font> damage and     business <font color="blue">interruption</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>currently has <font color="blue">insurance coverage</font> for     earthquake and <font color="blue">flood damage</font>, including business <font color="blue">interruption</font> coverage due to     those events, with limits of dlra5 million and subject to a <font color="blue">deductible which</font>     currently  is  <font color="blue">approximately</font>  dlra1dtta6 million</td>
    </tr>
    <tr>
      <td>There is no assurance that     earthquake or <font color="blue">flood insurance will continue</font> to be <font color="blue">available at</font> a cost that     is acceptable to the Company or that such insurance will be adequate to     reimburse our losses</td>
    </tr>
    <tr>
      <td>16       _________________________________________________________________    [58]Table of <font color="blue">Contents       </font>Industry Risks       Our <font color="blue">activities</font> involve <font color="blue">hazardous materials</font> and <font color="blue">improper handling</font> of these     <font color="blue">materials by</font> our employees or <font color="blue">agents could expose us</font> to <font color="blue">significant</font> legal     and <font color="blue">financial penalties</font></td>
    </tr>
    <tr>
      <td>Our  research and <font color="blue">development</font> <font color="blue">activities</font> involve the <font color="blue">controlled use</font> of     <font color="blue">hazardous materials</font>, including infectious agents, chemicals and various     <font color="blue">radioactive</font>  compounds</td>
    </tr>
    <tr>
      <td>Our  organic  chemists  use solvents, such as     chloroform, isopropyl alcohol and ethanol, corrosives such as hydrochloric     acid and other <font color="blue">highly flammable materials</font>, some of which are pressurized,     <font color="blue">such as hydrogen</font></td>
    </tr>
    <tr>
      <td>We use <font color="blue">radioactive</font> compounds in small <font color="blue">quantities under</font>     <font color="blue">license from</font> the State of California, including Carbon(14), Cesium(137),     Chromium(51), Hydrogen(3), Iodine(125), Phosphorus(32), Phosphorus(33) and     Sulfur(35)</td>
    </tr>
    <tr>
      <td>Our biologists use bio<font color="blue">hazardous materials</font>, such as bacteria,     fungi, parasites, viruses and blood and <font color="blue">tissue products</font></td>
    </tr>
    <tr>
      <td>We also handle     chemical, medical and <font color="blue">radioactive</font> waste, byproducts of our research, through     licensed  <font color="blue">contractors</font></td>
    </tr>
    <tr>
      <td>As  a  consequence, we are subject to numerous     <font color="blue">environmental</font> and safety laws and <font color="blue">regulations</font>, including those governing     <font color="blue">laboratory</font> procedures, exposure to blood-borne pathogens and the handling of     bio<font color="blue">hazardous materials</font></td>
    </tr>
    <tr>
      <td>Federal, state and <font color="blue">local governments may adopt</font>     <font color="blue">additional</font> laws and <font color="blue">regulations</font> affecting us in the future</td>
    </tr>
    <tr>
      <td>We may incur     substantial costs to <font color="blue">comply with</font>, and substantial fines or penalties if we     violate, current or <font color="blue">future laws</font> or <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>Although we believe that our <font color="blue">safety procedures</font> for using, handling, storing     and disposing of <font color="blue">hazardous materials</font> <font color="blue">comply with</font> the <font color="blue">standards prescribed by</font>     state and federal <font color="blue">regulations</font>, we <font color="blue">cannot eliminate</font> the risk of <font color="blue"><font color="blue">accident</font>al</font>     <font color="blue">contamination</font> or <font color="blue">injury from</font> these materials</td>
    </tr>
    <tr>
      <td>In the event of an <font color="blue">accident</font>,     state or <font color="blue">federal authorities may curtail</font> our use of these materials and we     could be liable for any <font color="blue">civil damages</font> that result, the cost of <font color="blue">which could</font>     be substantial</td>
    </tr>
    <tr>
      <td>Further, any failure by us to control the use, disposal,     removal or storage of, or to <font color="blue">adequately restrict</font> the discharge of, or assist     in the cleanup of, <font color="blue">hazardous chemicals</font> or hazardous, infectious or toxic     <font color="blue">substances could</font> subject us to <font color="blue">significant</font> <font color="blue">liabilities</font>, including joint and     several <font color="blue">liability</font> under state or <font color="blue">federal statutes</font></td>
    </tr>
    <tr>
      <td>We do not <font color="blue">specifically</font>     insure against <font color="blue">environmental</font> <font color="blue">liabilities</font> or risks regarding our handling of     <font color="blue">hazardous materials</font></td>
    </tr>
    <tr>
      <td>Additionally, an <font color="blue">accident</font> could damage, or force us to     shut down, our research <font color="blue">facilities</font> and <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>We  may  not  be  able  to  obtain or maintain <font color="blue">sufficient insurance on</font>     <font color="blue">commercially reasonable terms</font> or <font color="blue">with adequate coverage against potential</font>     <font color="blue">liabilities</font> in order to protect ourselves against product <font color="blue">liability</font> claims</td>
    </tr>
    <tr>
      <td>Our  business <font color="blue">exposes us</font> to potential product <font color="blue">liability</font> risks that are     inherent in the testing, manufacturing and marketing of <font color="blue">human therapeutic</font>     products</td>
    </tr>
    <tr>
      <td>We may become subject to product <font color="blue">liability</font> claims if someone     alleges that the use of our <font color="blue">products injured subjects</font> or patients</td>
    </tr>
    <tr>
      <td>This risk     exists for <font color="blue">products tested</font> in human <font color="blue">clinical trial</font>s as well as products that     are <font color="blue">sold commercially</font></td>
    </tr>
    <tr>
      <td>Although we currently have <font color="blue">insurance coverage</font> in     amounts that we believe are customary for companies of our size and in our     industry and sufficient for risks we <font color="blue">typically face</font>, including general     <font color="blue">liability</font> insurance of dlra6 million, we may not be able to maintain this type     of insurance in a <font color="blue">sufficient amount</font></td>
    </tr>
    <tr>
      <td>We currently maintain dlra5 million of     product <font color="blue">liability</font> insurance for claims arising from the use of our products     in <font color="blue">clinical trial</font>s</td>
    </tr>
    <tr>
      <td>In addition, product <font color="blue">liability</font> insurance is becoming     <font color="blue">increasingly</font>  expensive</td>
    </tr>
    <tr>
      <td>As a result, we may not be able to obtain or     maintain product <font color="blue">liability</font> insurance in the future on acceptable terms or     <font color="blue">with adequate coverage against potential</font> <font color="blue">liabilities</font> <font color="blue">which could</font> harm our     business by requiring us to use our resources to <font color="blue">pay potential</font> claims</td>
    </tr>
    <tr>
      <td>Market Risks       Because our stock is volatile, the value of your <font color="blue">investment</font> in <font color="blue">Genelabs </font>may     <font color="blue">substantially</font> decrease</td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font> of our <font color="blue">common stock</font>, like the <font color="blue">stock prices</font> of many publicly     traded bio<font color="blue"><font color="blue">pharmaceutical</font> companies</font>, has been and <font color="blue">will probably continue</font> to     be <font color="blue">highly volatile</font></td>
    </tr>
    <tr>
      <td><font color="blue">Between January </font>1, 2005 and <font color="blue">December </font>31, 2005, the price     of  our  <font color="blue">common stock</font> fluctuated between dlra1dtta70 and dlra6dtta15 per share, as     adjusted for the reverse-split</td>
    </tr>
    <tr>
      <td><font color="blue">Between January </font>1, 2006 and <font color="blue">February </font>28,     2006, the price of our <font color="blue">common stock</font> fluctuated between dlra1dtta73 and dlra2dtta30 per     share</td>
    </tr>
    <tr>
      <td>In addition to the <font color="blue">factors discussed</font> in this <font color="blue">Risk Factors </font>section, a     variety of events can impact the stock price, including the <font color="blue">low percentage</font>     of  <font color="blue">institutional ownership</font> of our stock, which contributes to lack of     stability for the stock price</td>
    </tr>
    <tr>
      <td>The <font color="blue">availability</font> of a large block of stock     for sale in relation to our <font color="blue">normal trading volume could also</font> result in a     decline in the <font color="blue">market price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>In the event we do not     obtain the                                         17       _________________________________________________________________    [59]Table of <font color="blue">Contents       </font>capital <font color="blue">necessary</font> to <font color="blue">continue as</font> a going concern, we may be required to     <font color="blue">discontinue</font>  <font color="blue">operations</font>,  which  could  result in the complete loss of     <font color="blue">investment</font> to our <font color="blue">shareholders</font></td>
    </tr>
    <tr>
      <td>In addition, numerous events occurring outside of our <font color="blue">control may also</font>     impact the price of our <font color="blue">common stock</font>, including <font color="blue">general market conditions</font> or     those  related to the bio<font color="blue">pharmaceutical</font> industry</td>
    </tr>
    <tr>
      <td>Other companies have     <font color="blue">defended themselves against securities</font> class <font color="blue">action lawsuits following</font>     periods of <font color="blue">volatility</font> in the <font color="blue">market price</font> of their <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>If a party     brings this type of lawsuit against us, it could result in substantial costs     and diversion of <font color="blue">management</font>’s time</td>
    </tr>
  </tbody>
</table>